Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NEOG vs VCYT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
VCYT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)
VCYT Overall Winner
6-Pillar Tally: NEOG 1 – 5 VCYT
Matrix Metrics: NEOG 3 – 7 VCYT
As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Neogen Corp (NEOG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NEOG carries a Unified Composite Score of 43.0/100 (HOLD) at $10.88 (36.3x Forward P/E, -0.8% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin).
- Technical & Structure Timing Caution: NEOG trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 36.3); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About NEOG vs VCYT
NEOG
Neogen Corp
$10.88
-3.12% 1D
Market Cap
$2.5B
TTM Revenue
$884M
Forward P/E
36.3x
Beta / 30D Vol
1.41β · 40% Vol
Unified Composite Score
43.0
HOLD
Tech 23.0
Fund 46.0
Flow 61.0
Mom 64.0
Weinstein Technical Phase
Neutral · Hold
VCYT
Head-to-Head Winner
Veracyte, Inc.
$24.01
-1.32% 1D
Market Cap
$2.0B
TTM Revenue
$582M
Forward P/E
15.3x
Beta / 30D Vol
3.01β · 199% Vol
Unified Composite Score
49.1
HOLD
Tech 55.0
Fund 56.0
Flow 57.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (NEOG 1 – 5 VCYT)
1. Valuation Multiples
VCYT
Forward P/E
36.3x
15.3x
Trailing P/E
16.0x
15.8x
PEG Ratio
0.66x
N/M
EV / Revenue
3.5x
3.1x
2. Growth & Scale
VCYT
Revenue Growth (YoY)
+6.5%
+15.1%
Earnings Growth (YoY)
-85.6%
+58.3%
TTM Revenue (USD)
$884M
$582M
Market Cap
$2.5B
$2.0B
3. Profitability & Quality
VCYT
Gross Margin
47.4%
74.2%
Operating Margin
-0.8%
15.0%
Net Profit Margin
-6.3%
21.8%
Return on Equity (ROE)
-2.7%
9.4%
4. Balance Sheet & Cash Flow
VCYT
Cash Generation (TTM)
$50M
$162M
Cash Flow Margin
5.6%
27.8%
Net Cash / Leverage
$602M Net Debt (0.37x D/E)
$159M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
NEOG
Options Structure Phase
CONSOLIDATION
BREAKDOWN
Current IV / %ile
46.0% (25th %ile)
197.3% (47th %ile)
Put/Call OI Skew
N/A
0.01x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
VCYT
OpEx & R&D Intensity
48.2% of Rev ($426M)
59.2% of Rev ($344M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Scale & Operating Efficiency Moat
Supply-Chain Role
Medical Devices Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: NEOG (3) vs VCYT (7)| Institutional Metric | NEOG | VCYT | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.5B | $2.0B | NEOG | |
| Trailing P/E Ratio | 16.0x | 15.8x | VCYT | |
| Forward P/E Ratio | 36.3x | 15.3x | VCYT | |
| Revenue Growth (YoY) | +6.5% | +15.1% | VCYT | |
| Operating Margin (TTM) | -0.8% | 15.0% | VCYT | |
| Net Profit Margin | -6.3% | 21.8% | VCYT | |
| Return on Equity (ROE) | -2.7% | 9.4% | VCYT | |
| 52-Week Range Position | 62% ($5–$14) | 5% ($22–$61) | NEOG | |
| Beta / 30D Volatility | 1.41β · 40% Vol | 3.01β · 199% Vol | NEOG | |
| Unified Institutional Score | 43.0 / 100 (HOLD) | 49.1 / 100 (HOLD) | VCYT | |
| Trailing 12M Revenue (USD) | $884M | $582M | Scale | |
| Gross Profit Margin (TTM) | 47.4% | 74.2% | Quality | |
| PEG Ratio & EV / Revenue | 0.66x PEG · 3.5x EV/Rev | N/M PEG · 3.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $50M ($602M Net Debt (0.37x D/E)) | $162M ($159M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
NEOG +36.45 pp
3M Horizon
NEOG +35.02 pp
6M Horizon
NEOG +69.24 pp
1Y Horizon
NEOG +110.58 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NEOG Revenue | VCYT Revenue | NEOG Op. Margin | VCYT Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $410M | $120M | 16.4% | -12.6% | NEOG |
| FY2020 | $420M | $120M | 16.1% | -30.1% | NEOG |
| FY2021 | $470M | $220M | 15.8% | -37.3% | NEOG |
| FY2022 | $530M | $300M | 11.1% | -13.9% | NEOG |
| FY2023 | $820M | $360M | 4.6% | -23.8% | NEOG |
| FY2024 | $920M | $450M | 6.3% | 3.6% | NEOG |
| FY2025 | $890M | $520M | -118.6% | 11.2% | VCYT |
| FY2026 | $870M | N/A | -2.5% | N/A | NEOG |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
NEOG
CONSOLIDATION
Current IV
46.0%
IV Percentile
25th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact NEOG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
VCYT
BREAKDOWN
Current IV
197.3%
IV Percentile
47th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
NEOG Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
48.2% of Rev ($426M)
90D Engineering Disclosures
0 Published
VCYT Moat Profile
Scale & Operating Efficiency Moat
Diagnostics & Research Operator
OpEx & R&D Reinvestment
59.2% of Rev ($344M)
90D Engineering Disclosures
0 Published
Investor FAQ NEOG vs VCYT Key Questions & Quantitative Answers
As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Neogen Corp (NEOG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NEOG carries a Unified Composite Score of 43.0/100 (HOLD) at $10.88 (36.3x Forward P/E, -0.8% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin). Technical & Structure Timing Caution: NEOG trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 36.3); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VCYT leads the Growth & Scale pillar: NEOG posts +6.5% YoY revenue growth and -85.6% YoY earnings growth on $884M TTM revenue (47.4% gross margin, -0.8% operating margin), compared with VCYT at +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), NEOG cumulative revenue shifted +112.2% while VCYT shifted +333.3%. In operating R&D and SG&A reinvestment, NEOG deploys 48.2% of Rev ($426M) (0 90-day corporate R&D disclosures) versus 59.2% of Rev ($344M) (0 disclosures) for VCYT.
VCYT screens cheaper on headline valuation multiples. NEOG trades at 36.3x Forward P/E, 16.0x Trailing P/E, 0.66x PEG, and 3.5x EV/Revenue (5.6% FCF margin), whereas VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NEOG (-2.7% ROE) versus VCYT (9.4% ROE) capital efficiency.
In options market volatility and institutional positioning, NEOG carries 46.0% implied volatility (25th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.41β · 40% Vol realized risk). By comparison, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
VCYT vs NEOG · Reverse Pair
NEOG vs MMSI
· Sector Peer
NEOG vs ICUI
· Sector Peer
NEOG vs EXPO
· Sector Peer
VCYT vs CDNA
· Sector Peer
VCYT vs TWST
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem